Pharma Equity Group A/S financials
Pharma Equity Group A/S
2138008SUI4D917FKN20 | Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | DKK 0 | DKK 0 |
| Cost of sales | DKK 0 | DKK 0 |
| Gross profit | DKK 0 | DKK 0 |
| Administrative expenses | DKK 12.1M | DKK 12.3M |
| Operating profit (EBIT) | -DKK 17.2M | -DKK 21.3M |
| Finance costs | DKK 2.7M | DKK 5.0M |
| Profit before tax | -DKK 26.4M | -DKK 42.4M |
| Income tax expense | -DKK 1.0M | -DKK 1.8M |
| Profit for the year | -DKK 25.4M | -DKK 40.6M |
| Total comprehensive income | -DKK 25.4M | -DKK 40.6M |
| Per share | ||
| Basic EPS | DKK -2.00 | DKK -2.00 |
| Diluted EPS | DKK -2.00 | DKK -2.00 |
| Free cash flow / share | DKK -1.39 | DKK -1.13 |
| Cash flow statement | ||
| Cash generated from operations | -DKK 17.1M | -DKK 21.0M |
| Net cash from operating activities | -DKK 17.7M | -DKK 22.9M |
| Net cash from investing activities | DKK 11.0K | DKK 0 |
| Purchase of PP&E (capex) | -DKK 11.0K | DKK 0 |
| Net cash from financing activities | DKK 13.9M | DKK 22.9M |
| Dividends paid | DKK 0 | DKK 0 |
| Lease liability payments | DKK 309.0K | DKK 245.0K |
| Balance sheet | ||
| Total assets | DKK 38.9M | DKK 49.4M |
| Non-current assets | DKK 637.0K | DKK 271.0K |
| Property, plant & equipment | DKK 0 | DKK 37.0K |
| Right-of-use assets | DKK 637.0K | DKK 234.0K |
| Current assets | DKK 38.3M | DKK 49.1M |
| Cash & equivalents | DKK 498.0K | DKK 4.2M |
| Total equity | DKK 25.5M | DKK 32.7M |
| Non-current liabilities | DKK 4.6M | DKK 8.1M |
| Lease liabilities (non-current) | DKK 421.0K | DKK 0 |
| Current liabilities | DKK 8.8M | DKK 8.6M |
| Lease liabilities (current) | DKK 216.0K | DKK 234.0K |
| Derived metrics | ||
| Free cash flow | -DKK 17.6M | -DKK 22.9M |
| Return on equity | -99.6% | -124.2% |
| Cash conversion ratio | 0.70× | 0.56× |
| Capex coverage | 1605.55× | — |
| Other reported items | ||
| Adjustments For Decrease Increase In Prepaid Expenses | DKK 234.0K | -DKK 390.0K |
| Adjustments For Decrease Increase In Trade Account Receivable | -DKK 167.0K | DKK 1.9M |
| Adjustments For Depreciation and Amortisation Expense | DKK 311.0K | DKK 235.0K |
| Adjustments For Finance Costs | DKK 2.7M | DKK 5.0M |
| Adjustments For Finance Income | -DKK 1.5M | -DKK 14.0K |
| Adjustments For Increase Decrease In Other Liabilities | -DKK 82.0K | -DKK 382.0K |
| Adjustments For Increase Decrease In Trade Account Payable | -DKK 232.0K | -DKK 1.1M |
| Current Prepaid Expenses | DKK 579.0K | DKK 813.0K |
| Current Tax Assets Current | DKK 2.8M | DKK 1.8M |
| Current Unsecured Bank Loans Received and Current Portion of Noncurrent Unsecured Bank Loans Received | DKK 0 | DKK 1.2M |
| Equity and Liabilities | DKK 38.9M | DKK 49.4M |
| Finance Costs Paid Classified As Operating Activities | -DKK 561.0K | -DKK 4.1M |
| Finance Income | DKK 1.5M | DKK 14.0K |
| Finance Income Received Classified As Operating Activities | DKK 10.0K | DKK 14.0K |
| Income Taxes Refund Classified As Operating Activities | DKK 0 | DKK 2.2M |
| Increase Decrease In Cash and Cash Equivalents | -DKK 3.7M | DKK 3.0K |
| Increase Decrease Through Transactions With Owners | DKK 18.2M | DKK 48.0M |
| Issue of Convertible Instruments | DKK 20.0M | — |
| Issue of Equity | — | DKK 51.1M |
| Issued Capital | DKK 122.8M | DKK 122.8M |
| Liabilities | DKK 13.4M | DKK 16.7M |
| Loans Received | DKK 3.2M | DKK 1.5M |
| Other Comprehensive Income | DKK 0 | DKK 0 |
| Other Current Liabilities | DKK 1.5M | DKK 1.6M |
| Other Receivables | DKK 639.0K | DKK 472.0K |
| Other Reserves | -DKK 115.5M | -DKK 90.1M |
| Payments For Share Issue Costs | DKK 0 | DKK 8.2M |
| Proceeds From Issue of Subordinated Liabilities | DKK 0 | DKK 11.0M |
| Proceeds From Issuing Other Equity Instruments | DKK 17.1M | DKK 0 |
| Proceeds From Issuing Shares | DKK 0 | DKK 51.1M |
| Proceeds From Noncurrent Borrowings | DKK 3.0M | DKK 13.1M |
| Repayments of Current Borrowings | DKK 1.2M | DKK 2.9M |
| Repayments of Noncurrent Borrowings | DKK 0 | DKK 29.4M |
| Repayments of Subordinated Liabilities | DKK 4.6M | DKK 11.6M |
| Research and Development Expense | DKK 5.1M | DKK 9.0M |
| Reserve of Equity Component of Convertible Instruments | DKK 18.2M | DKK 0 |
| Share Issue Related Cost | — | DKK 3.2M |
| Subordinated Liabilities | DKK 4.2M | DKK 8.1M |
| Trade and Other Payables To Trade Suppliers | DKK 3.9M | DKK 4.1M |
Every line item above is a fact tagged in Pharma Equity Group A/S's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (DKK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.